CD274 and neoplasm: More and more studies have also confirmed that tumour mutation burden (TMB) is considered as a surrogate indicator to predict the efficacy of pan-tumour immunotherapy, and is also one of the biomarkers to predict the immune efficacy of metastatic lung cancer in addition to PD-L1 expression [100, 101].